{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 31 of 51', 'Study ID RCB: 2020-A00652-37', 'If a patient is erroneously included in the study more than once only the data relating to the', 'first inclusion will be kept in the database and be available for analysis. Data from later', 'inclusions will be transferred to the first dataset when relevant, i.e. if collected within the time', 'frame of the first follow-up period.', 'If', 'a patient is included in the study in spite of not being treated according to the approved', 'terms of the marketing authorization, data is kept in the database and analysed separately and', 'as part of the overall analyses as described in the Statistical Analysis Plan.', 'LEO owns the data collected in the CRF and as PRO. General Data Protection Regulation', '(European Commission, 2016) (GDPR) must be adhered to, in addition to any local laws and', 'regulations regarding data privacy. The study must follow the EFPIA HCP Code Article 15 Non-', 'Interventional Studies of Marketed Medicines (The European Federation of Pharmaceutical', 'Industries and Associations, 2008).', 'The Study Master File compiled by the CRO should be transferred to LEO affiliate when', 'complete. The Complete Study Master File comprises both LEO and CRO compiled documents', 'but should not hold duplicates.', 'The Study Database compiled by CRO should be transferred to LEO HQ when complete.', 'Safety data collection and reporting from this NIS must follow the current version of the EMA', 'Guideline on Good pharmacovigilance practices (GVP) Module VI - Management and', 'reporting of adverse reactions to medicinal products (European Medicines Agency, 2017). For', 'reporting please refer to Section 11.', 'The data extracted from medical records and databases is not owned by LEO. The collection', 'must be guided by relevant guidance documents, e.g. Guidance for Industry and FDA Staff:', 'Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using', 'Electronic Healthcare Data (Food and Drug Administration, 2013), the ISPOR Good Research.', 'Practice for Retrospective Database Analysis Task Force Report (Berger et al., 2009), and the', 'European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)', 'Guide on Methodological Standards in Pharmacoepidemiology and Code of Conduct', '(European Medicines Agency, 2010).', 'When collecting database data, collection and submission of single case safety data is not', 'required. For data collected from medical records, please refer to Section 11.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 32 of 51', 'Study ID RCB: 2020-A00652-37', '9.7 Data Analysis', 'This study is observational and epidemiological methods will be employed for data analyses.', 'Descriptive analysis will be performed of all collected data, except data collected only for the', 'purpose of data cleaning.', 'Section 9.7.1 describes the statistical analyses as foreseen at the time of planning the study.', 'Any known deviations from the planned analyses, the reason for such deviations and all', 'alternative/additiona statistical analyses that may be performed as well as the final statistical', 'analysis must be described in a revised Statistical Analysis Plan (SAP) before completion of data', 'collection. All later deviations and/or alterations will be summarised in the Clinical Study', 'Report.', '9.8 Statistical Analysis Plan', 'Data analyses will be performed using SAS Version 9.4 or further (SAS Institute, Cary, NC USA', 'software).', 'Quantitative parameters will be described using the following summary descriptive statistics:', 'number of non-missing values, mean, standard deviation, median, first and third quartiles, and', 'minimum and maximum values.', 'Qualitative parameters will be described overall using frequencies and percentages.', 'Percentages will be calculated on the number of non-missing observations.', 'The level of significance for all comparisons is set at 0.05 using two-tailed tests. Confidence', 'intervals at 95% could be provided, if relevant.', '9.8.1', 'Description of the population', 'The safety population will comprise all included patients having received at least one dose of', 'treatment.', 'The efficacy population will comprise all included patients who fulfill all inclusion and exclusion', 'criteria.', 'The total number of patients included in the study, in each analysis population and related', 'reasons of exclusion will be described.', 'The total number of patients attended each visit, number and reasons of study discontinuation', 'will also be described.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}